Viromed Medical AG Initiates Cold Plasma Study on Living Lungs

Viromed Medical AG, a leader in cold plasma technology, has announced the start of an in vivo and ex vivo study on living lungs. This study, conducted with Hannover Medical School, focuses on treating ventilator-associated pneumonia (VAP) using cold atmospheric plasma. The promising results from preliminary in vitro tests pave the way for this groundbreaking research.

Prof. Dr. Hortense Slevogt highlighted the potential of cold atmospheric plasma in revolutionizing treatment for ventilated patients. Uwe Perbandt, CEO of Viromed, emphasized the study's global significance in pulmonology. The study aims to reduce mortality from VAP and other lung infections, based on evidence of cold plasma's effectiveness against MRSA without harming lung tissue.

The comprehensive study will explore the interaction between respiratory epithelium, bacterial infection, and cold plasma therapy under realistic conditions. Results will be published in a fast-track paper, positioning Viromed at the forefront of medical research innovation.